natgillin/translations-raw huggingface dataset:
Following two applications from Pharma Consulting & Industries submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of I omega kids®/Pufan 3 kids® on learning ability (Question No EFSA-Q-2008-102 and Question No EFSA-Q-2008-103) [22].
Družba Pharma Consulting & Industries je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogi, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi I omega kids®/Pufan 3 kids® na zmožnost učenja (vprašanje št. EFSA-Q-2008-102 in vprašanje št. EFSA-Q-2008-103) [22].
The claim proposed by the applicant was worded as follows: ‘help to support the learning ability’.
Vlagatelj je predlagal naslednjo trditev: „Pomaga pri povečanju zmožnosti učenja“.
The comments from the applicants and the members of the public received by the Commission pursuant to Article 16(6) of Regulation (EC) No 1924/2006 have been considered when setting the measures provided for in this Regulation.
Pri določanju ukrepov iz te uredbe so bile upoštevane pripombe, ki so jih vlagatelj in predstavniki javnosti poslali Komisiji v skladu s členom 16(6) Uredbe (ES) št. 1924/2006.
In accordance with Article 28(6) of Regulation (EC) No 1924/2006 health claims as referred to in Article 14(1)(b) of that Regulation and not authorised by this Regulation may continue to be used for six months after the adoption of a decision pursuant to Article 17(3) of Regulation (EC) No 1924/2006.
Zdravstvene trditve iz člena 14(1)(b) Uredbe (ES) št. 1924/2006, ki niso odobrene s to uredbo, se lahko v skladu s členom 28(6) navedene uredbe uporabljajo šest mesecev po sprejetju odločbe v skladu s členom 17(3) Uredbe (ES) št. 1924/2006.
However, for applications which were not made before 19 January 2008, the requirement provided for in Article 28(6)(b) is not fulfilled, and the transition period laid down in that Article is not applicable.
Vloge, ki niso bile predložene do 19. januarja 2008, ne izpolnjujejo zahteve iz člena 28(6)(b), zato se prehodno obdobje iz navedenega člena ne uporablja.
Accordingly, a transition period of six months should be provided for, to enable food business operators to adapt to the requirements laid down in this Regulation.
Zato je treba zagotoviti šestmesečno prehodno obdobje, da se lahko nosilci živilske dejavnosti prilagodijo zahtevam iz te uredbe.
The health claims set out in Annex I to this Regulation may be made on food on the Community market in compliance with the conditions set out in that Annex.
Zdravstvene trditve iz Priloge I k tej uredbi se lahko navedejo na živilih na trgu Skupnosti pod pogoji iz navedene priloge.
Those health claims shall be included in a list of permitted claims referred to in Article 14(1) of Regulation (EC) No 1924/2006.
Navedene zdravstvene trditve se vključijo na seznam dovoljenih trditev iz člena 14(1) Uredbe (ES) št. 1924/2006.
The health claims set out in Annex II to this Regulation are rejected.
Zdravstvene trditve iz Priloge II k tej uredbe se zavrnejo.
Health claims as referred to in Article 14(1)(b) of Regulation (EC) No 1924/2006 and set out in Annex II to this Regulation may continue to be used for six months after the entry into force of this Regulation.
Zdravstvene trditve iz člena 14(1)(b) Uredbe (ES) št. 1924/2006, ki so naštete v Prilogi II k tej uredbi, se lahko uporabljajo še šest mesecev po začetku veljavnosti te uredbe.
The EFSA Journal (2008) 781, 1-2.
The EFSA Journal (2008) 781, str. 1–2.
The EFSA Journal (2008) 825, 1-13.
The EFSA Journal (2008) 825, str. 1–13.
The EFSA Journal (2008) 783, 1-10.
The EFSA Journal (2008) 783, str. 1–10.
The EFSA Journal (2008) 827, 1-2.
The EFSA Journal (2008) 827, str. 1–2.
The EFSA Journal (2008) 828, 1-13.
The EFSA Journal (2008) 828, str. 1–13.
The EFSA Journal (2008) 826, 1-11.
The EFSA Journal (2008) 826, str. 1–11.
The EFSA Journal (2008) 858, 1-2.
The EFSA Journal (2008) 858, str. 1–2.
The EFSA Journal (2008) 788, 1-2.
The EFSA Journal (2008) 788, str. 1–2.
The EFSA Journal (2008) 824, 1-2.
The EFSA Journal (2008) 824, str. 1–2.
The EFSA Journal (2008) 794, 1-2.
The EFSA Journal (2008) 794, str. 1–2.
The EFSA Journal (2008) 787, 1-2.
The EFSA Journal (2008) 787, str. 1–2.
The EFSA Journal (2008) 786, 1-10.
The EFSA Journal (2008) 786, str. 1–10.
The EFSA Journal (2008) 782, 1-2.
The EFSA Journal (2008) 782, str. 1–2.
The EFSA Journal (2008) 829, 1-10.
The EFSA Journal (2008) 829, str. 1–10.
The EFSA Journal (2008) 830, 1-2.
The EFSA Journal (2008) 830, str. 1–2.
The EFSA Journal (2008) 831, 1-2.
The EFSA Journal (2008) 831, str. 1–2.
The EFSA Journal (2008) 832, 1-8.
The EFSA Journal (2008) 832, str. 1–8.
The EFSA Journal (2008) 847, 1-10.
The EFSA Journal (2008) 847, str. 1–10.
The EFSA Journal (2008) 846, 1-10.
The EFSA Journal (2008) 846, str. 1–10.
The EFSA Journal (2008) 845, 1-2.
The EFSA Journal (2008) 845, str. 1–2.
The EFSA Journal (2008) 848, 1-10.
The EFSA Journal (2008) 848, str. 1–10.
PERMITTED HEALTH CLAIMS
DOVOLJENE ZDRAVSTVENE TRDITVE
Application – Relevant provisions of Regulation (EC) No 1924/2006
Vloga – ustrezne določbe Uredbe (ES) št. 1924/2006
Applicant – Address
Vlagatelj –naslov
Article 14(1)(a) health claim referring to reduction of disease risk
Zdravstvena trditev v skladu s členom 14(1)(a), ki se nanaša na zmanjšanje tveganja za bolezen
and Unilever NV, Weena 455, Rotterdam, 3013 AL, Nederland
in Unilever N.V.Weena 455, Rotterdam, 3013 AL, Nizozemska
Plant sterols: Sterols extracted from plants, free or esterified with food grade fatty acids
rastlinski steroli: steroli, ekstrahirani iz rastlin, prosti ali v obliki estrov maščobnih kislin živilske kakovosti
Plant sterols have been shown to lower/reduce blood cholesterol.
Rastlinski steroli dokazano bistveno znižujejo holesterol v krvi.
High cholesterol is a risk factor in the development of coronary heart disease
Povišan holesterol je dejavnik tveganja za razvoj koronarne bolezni srca.
Information to the consumer that the beneficial effect is obtained with a daily intake of at least 2 g plant sterols
Informacija potrošniku, da se koristni učinek doseže z dnevnim vnosom vsaj dveh gramov (2 g) rastlinskih sterolov.
McNeil Nutritionals, 1 Landis und Gyr Strasse, 6300 Zug; Switzerland
McNeil Nutritionals, 1 Landis und Gyr Strasse, 6300 Zug; Švica
Plant stanol esters
estri rastlinskih stanolov
Plant stanol esters have been shown to lower/reduce blood cholesterol.
Estri rastlinskih stanolov dokazano bistveno znižujejo holesterol v krvi.
Information to the consumer that the beneficial effect is obtained with a daily intake of at least 2 g plant stanols
Informacija potrošniku, da se koristni učinek doseže z dnevnim vnosom vsaj dveh gramov (2 g) rastlinskih stanolov.
Article 14(1)(b) health claim referring to children’s development and health
Zdravstvena trditev v skladu s členom 14(1)(b), ki se nanaša na razvoj in zdravje otrok
α-linolenic acid & linoleic acid
α-linolenska kislina in linolna kislina
Essential fatty acids are needed for normal growth and development of children
Esencialne maščobne kisline so potrebne za normalno rast in razvoj otrok.
Information to the consumer that the beneficial effect is obtained with a daily intake of 1 % of total energy for linoleic acid and 0,2 % of total energy of α-linolenic acid
Informacija potrošniku, da se koristni učinek doseže z dnevnim vnosom linolne kisline, ki predstavlja 1 % celotnega energijskega vnosa, in dnevnim vnosom α-linolenske kisline, ki predstavlja 0,2 % celotnega energijskega vnosa.
Association de la Transformation Laitière Française (ATLA), 42, rue du Châteaudun, 75314 Paris Cedex 09, FRANCE
Association de la Transformation Laitière Française (ATLA), 42, rue du Châteaudun, 75314 Pariz Cedex 09, Francija
Calcium is needed for normal growth and development of bone in children
Kalcij je potreben za normalno rast in razvoj kosti otrok.
The claim can be used only for food which is at least a source of calcium as referred to in the claim SOURCE OF [NAME OF VITAMIN/S] AND/OR [NAME OF MINERAL/S] as listed in the Annex to Regulation (EC) No 1924/2006
Trditev se lahko navede le na živilu, ki je vsaj vir kalcija, kakor je opredeljeno s trditvijo VIR [IME VITAMINA/VITAMINOV] IN/ALI [IME MINERALA/MINERALOV] iz Priloge k Uredbi (ES) št. 1924/2006.
Protein is needed for normal growth and development of bone in children
Beljakovine so potrebne za normalno rast in razvoj kosti otrok.
The claim can be used only for food which is at least a source of protein as referred to in the claim SOURCE OF PROTEIN as listed in the Annex to Regulation (EC) No 1924/2006
Trditev se lahko navede le na živilu, ki je vsaj vir beljakovin, kakor je opredeljeno s trditvijo VIR BELJAKOVIN iz Priloge k Uredbi (ES) št. 1924/2006.
Yoplait Dairy Crest Ltd, Claygate House, Claygate, Surrey, KT10 9PN, UK
Yoplait Dairy Crest Ltd., Claygate House, Claygate, Surrey, KT10 9PN, Združeno kraljestvo
Calcium and vitamin D
kalcij in vitamin D
Calcium and vitamin D are needed for normal growth and development of bone in children
Kalcij in vitamin D sta potrebna za normalno rast in razvoj kosti otrok.
The claim can be used only for food which is at least a source of calcium and vitamin D as referred to in the claim SOURCE OF [NAME OF VITAMIN/S] AND/OR [NAME OF MINERAL/S] as listed in the Annex to Regulation (EC) No 1924/2006
Trditev se lahko navede le na živilu, ki je vsaj vir kalcija in vitamina D, kakor je opredeljeno v trditvi VIR [IME VITAMINA/VITAMINOV] IN/ALI [IME MINERALA/MINERALOV] iz Priloge k Uredbi (ES) št. 1924/2006.
Vitamin D is needed for normal growth and development of bone in children
Vitamin D je potreben za normalno rast in razvoj kosti otrok.
The claim can be used only for food which is at least a source of Vitamin D as referred to in the claim SOURCE OF [NAME OF VITAMIN/S] AND/OR [NAME OF MINERAL/S] as listed in the Annex to Regulation (EC) No 1924/2006
Trditev se lahko navede le na živilu, ki je vsaj vir vitamina D, kakor je opredeljeno v trditvi VIR [IME VITAMINA/VITAMINOV] IN/ALI [IME MINERALA/MINERALOV] iz Priloge k Uredbi (ES) št. 1924/2006.
REJECTED HEALTH CLAIMS
ZAVRNJENE ZDRAVSTVENE TRDITVE
NeOpuntia® helps to improve blood lipid parameters associated with cardiovascular risks, especially the HDL-cholesterol
NeOpuntia® pomaga izboljšati raven lipidov v krvi, povezanih s kardiovaskularnim tveganjem, zlasti HDL-holesterola.
Lactobacillus helveticus fermented Evolus®low-fat milk products
mlečni izdelki z manj maščobe Evolus®, fermentirani z Lactobacillus helveticus
Evolus® reduces arterial stiffness
Evolus® zmanjša togost arterij.
regulat®.pro.kid IMMUN supports, stimulates and modulates the immune system of children during growth
regulat®.pro.kid IMMUN podpira, spodbuja in krepi imunski sistem otrok v obdobju rasti.
Dairy products
mleko in mlečni izdelki
Three portions of dairy food everyday, as part of a balanced diet, may help promote a healthy body weight during childhood and adolescence
Trije obroki mleka in mlečnih izdelkov dnevno kot del uravnotežene prehrane lahko pomagajo pri vzdrževanju zdrave telesne teže v otroštvu in mladostništvu.
Dairy foods (milk & cheese) promote dental health in children
Mleko in mlečni izdelki (mleko in sir) krepijo zdravje zob otrok.
Docosahexaenoic Acid (DHA) and Arachidonic Acid (ARA)
dokosaheksenojska (DHA) in arahidonska kislina (ARA)
DHA and ARA support neural development of the brain and eyes
DHA in ARA podpirata razvoj živčevja v možganih in očeh.
regulat®.pro.kid BRAIN contributes to mental and cognitive development of children
regulat®.pro.kid BRAIN pomaga pri duševnem in kognitivnem razvoju otrok.
Docosahexaenoic Acid (DHA) and eicosapentaenoic acid (EPA)
dokosaheksenojska kislina (DHA) in eikosapentenojska kislina (EPA)
Calming
Pomirja.
EFSA-Q-2008-091 and
EFSA-Q-2008-091 in
Provide serenity and room for a beneficial development of the child
Zagotavlja umirjenost in zmožnost za razvoj otroka.
EFSA-Q-2008-092 and
EFSA-Q-2008-092 in
Help to support vision
Pomaga pri razvoju vida.
EFSA-Q-2008-095 and
EFSA-Q-2008-095 in
Help to support mental development
Pomaga pri duševnem razvoju.
EFSA-Q-2008-098 and
EFSA-Q-2008-098 in
Help to promote concentration
Pomaga pri izboljšanju zbranosti.
EFSA-Q-2008-094 and
EFSA-Q-2008-094 in
Helps to promote the thinking capacity
Pomaga pri povečanju miselne zmožnosti.
EFSA-Q-2008-093 and
EFSA-Q-2008-093 in
Help to support the learning ability
Pomaga pri povečanju zmožnosti učenja.
EFSA-Q-2008-102 and
EFSA-Q-2008-102 in
Unilever PLC; Port Sunlight, Wirral, Merseyside, CH62 4ZD, UK
Unilever PLC; Port Sunlight, Wirral, Merseyside, CH62 4ZD, Združeno kraljestvo
Commission Regulation (EC) No 984/2009
Uredba Komisije (ES) št. 984/2009
refusing to authorise certain health claims made on food, other than those referring to the reduction of disease risk and to children’s development and health
o zavrnitvi odobritve nekaterih zdravstvenih trditev na živilih, razen tistih, ki se nanašajo na zmanjšanje tveganja za nastanek bolezni ter na razvoj in zdravje otrok
Having regard to Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods [1], and in particular Article 18(5) thereof,
ob upoštevanju Uredbe (ES) št. 1924/2006 Evropskega parlamenta in Sveta z dne 20. decembra 2006 o prehranskih in zdravstvenih trditvah na živilih [1] ter zlasti člena 18(5) Uredbe,
Following receipt of an application the Authority is to inform without delay the other Member States and the Commission and to deliver an opinion on a health claim concerned.
Agencija po prejemu vloge nemudoma obvesti druge države članice in Komisijo ter pripravi mnenje o zadevni zdravstveni trditvi.
The Commission is to decide on the authorisaton of health claims taking into account the opinion delivered by the Authority.
Komisija ob upoštevanju mnenja Agencije odloči o odobritvi zdravstvenih trditev.
Following an application from Pierre Fabre Dermo Cosmétique submitted on 14 April 2008 pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Elancyl Global Silhouette® on the regulation of body composition in people with light to moderate overweight (Question No EFSA-Q-2008-285) [2].
Družba Pierre Fabre Dermo Cosmetique je 14. aprila 2008 v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki Elancyl Global Silhouette® na sestavo telesa pri ljudeh z lažje do zmerno povišano telesno težo (Vprašanje št. EFSA-Q-2008-285) [2].
The claim proposed by the applicant was worded as follows: ‘Clinically tested as of 14 days.
Vlagatelj je predlagal naslednjo trditev: „Klinično testiranje opravljeno po 14-dnevni uporabi izdelka.
Your silhouette is apparently and globally redrawn, resculpted and refined at 28 days’.
Vaša postava se bo po 28 dneh vidno in znatno izboljšala.“
On 12 August 2008, the Commission and the Member States received the scientific opinion from the Authority which concluded that on the basis of the data presented, a cause and effect relationship was not established between the consumption of Elancyl Global Silhouette® in the quantities and duration proposed by the applicant and the claimed effect.
Komisija in države članice so 12. avgusta 2008 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov sklenila, da vzročno-posledična povezava med uporabo Elancyl Global Silhouette® v količinah in časovnem obdobju, kot ju predlaga vlagatelj, in navedenim učinkom ni utemeljena.
Following an application from Valio Ltd submitted on 8 July 2008, pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of LGG® MAX on gastro-intestinal discomfort (Question No EFSA-Q-2008-444) [3].
Družba Valio Ltd je 8. julija 2008 v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki LGG® MAX na prebavne težave (Vprašanje št. EFSA-Q-2008-444) [3].
The claim proposed by the applicant was worded as follows: ‘LGG® MAX helps to reduce gastro-intestinal discomfort’.
Vlagatelj je predlagal naslednjo trditev: „LGG® MAX pomaga pri lajšanju prebavnih težav.“
On 30 August 2008 the Commission and the Member States received the scientific opinion from the Authority which concluded that on the basis of the data presented, a cause and effect relationship was not established between the consumption of LGG® MAX (Mixture A or Mixture B) and the claimed effect.
Komisija in države članice so 30. avgusta 2008 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov sklenila, da vzročno-posledična povezava med uporabo LGG® MAX (mešanica A ali mešanica B) in navedeno trditvijo ni utemeljena.
The comments from the applicants and the members of the public received by the Commission, pursuant to Article 16(6) of Regulation (EC) No 1924/2006, have been considered when setting the measures provided for in this Regulation.
Pri določanju ukrepov iz te uredbe so bile upoštevane pripombe, ki so jih vlagatelj in predstavniki javnosti poslali Komisiji v skladu s členom 16(6) Uredbe (ES) št. 1924/2006.
The health claim ‘LGG® MAX helps to reduce gastro-intestinal discomfort’ is a health claim as referred to Article 13(1)(a) of Regulation (EC) No 1924/2006 and therefore subject to the transition measure laid down in Article 28(5) of that Regulation.
Zdravstvena trditev „LGG® MAX pomaga pri lajšanju prebavnih težav“ je zdravstvena trditev v smislu člena 13(1)(a) Uredbe (ES) št. 1924/2006 in je predmet prehodnega ukrepa iz člena 28(5) navedene uredbe.
As the Authority concluded that a cause and effect relationship is not established between the consumption of LGG® MAX and the claimed effect the claim does not comply with Regulation (EC) No 1924/2006, and therefore the transition period foreseen in Article 28(5) is not applicable.
Ker je Agencija sklenila, da vzročno-posledična povezava med uporabo LGG®MAX in navedeno trditvijo ni utemeljena, navedena trditev ni v skladu z Uredbo (ES) št. 1924/2006, zato se prehodno obdobje iz člena 28(5) ne uporablja.
A transition period of six months should be provided for, to enable food business operators to adapt to the requirements of Regulation (EC) No 1924/2006.
Zagotoviti je treba šestmesečno prehodno obdobje, da se lahko nosilci živilske dejavnosti prilagodijo zahtevam iz Uredbe (ES) št. 1924/2006.
The health claim ‘Clinically tested as of 14 days.
Zdravstvena trditev „Klinično testiranje opravljeno po 14-dnevni uporabi izdelka.
Your silhouette is apparently and globally redrawn, resculpted and refined at 28 days’ is a health claim as referred to Article 13(1)(c) of Regulation (EC) No 1924/2006 and therefore subject to the transition measure laid down in Article 28(6) of that Regulation.
Vaša postava se bo po 28 dneh vidno izboljšala“ je zdravstvena trditev v smislu člena 13(1)(c) Uredbe (ES) št. 1924/2006 in je predmet prehodnega ukrepa iz člena 28(6) navedene uredbe.
However, as the application was not made before 19 January 2008, the requirement provided for in Article 28(6)(b) is not fulfilled, and the transition period laid down in that Article is not applicable.
Ker vloga ni bila predložena pred 19. januarjem 2008, zahteva iz člena 28(6)(b) ni izpolnjena, zato se prehodno obdobje iz navedenega člena ne uporablja.
Accordingly, a transition period of six months should be provided for, to enable food business operators to adapt to the requirements of this Commission Regulation.
Zagotoviti je treba šestmesečno prehodno obdobje, da se lahko nosilci živilske dejavnosti prilagodijo zahtevam iz te uredbe.
Health claims set out in the Annex to this Regulation may not be made on food on the Community market.
Zdravstvene trditve iz Priloge k tej uredbi se ne smejo navesti na živilih na trgu Skupnosti.
Health claims set out in the Annex to this Regulation may continue to be used for six months after the entry into force of this Regulation.
Zdravstvene trditve iz Priloge k tej uredbi se lahko uporabljajo še šest mesecev po začetku veljavnosti te uredbe.
The EFSA Journal (2008) 789, pp. 1-2.
The EFSA Journal (2008) 789, str. 1–2.
The EFSA Journal (2008) 853, pp. 1-2.
The EFSA Journal (2008) 853, str. 1–2.
Application — Relevant provisions of Regulation (EC) No 1924/2006
Vloga – ustrezne določbe Uredbe (ES) št. 1924/2006
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
Zdravstvena trditev v smislu člena 13(5), ki je utemeljena na novo ugotovljenih znanstvenih dokazih in/ali vključuje zahtevo za zakonsko zaščito podatkov
Clinically tested as of 14 days.
Klinično testiranje opravljeno po 14-dnevni uporabi izdelka.
Your silhouette is apparently and globally redrawn, resculpted and refined at 28 days
Vaša postava se bo po 28 dneh vidno izboljšala.
LGG® MAX multispecies probiotic
LGG® MAX probiotik z več vrstami
LGG® MAX helps to reduce gastro-intestinal discomfort
LGG® MAX pomaga pri lajšanju prebavnih težav.
Commission Regulation (EC) No 985/2009
Uredba Komisije (ES) št. 985/2009
Pursuant to the first subparagraph of Article 6(2) and in accordance with Article 17(2) of Regulation (EC) No 510/2006, Hungary’s application to register the name ‘Hajdúsági torma’ was published in the Official Journal of the European Union [2].
V skladu s prvim pododstavkom člena 6(2) in členom 17(2) Uredbe (ES) št. 510/2006 je bila vloga Madžarske za registracijo imena „Hajdúsági torma“ objavljena v Uradnem listu Evropske unije [2].
OJ C 39, 18.2.2009, p. 32.
UL C 39, 18.2.2009, str. 32.
Hajdúsági torma [PDO]
Hajdúsági torma (ZOP)
Commission Regulation (EC) No 986/2009
Uredba Komisije (ES) št. 986/2009
Pursuant to the first subparagraph of Article 6(2) and to Article 17(2) of Regulation (EC) No 510/2006, the United Kingdom’s application to register the name ‘Traditional Grimsby Smoked Fish’ was published in the Official Journal of the European Union [2].
V skladu s prvim pododstavkom člena 6(2) in členom 17(2) Uredbe (ES) št. 510/2006 je bila vloga Združenega kraljestva za registracijo imena „Traditional Grimsby Smoked Fish“ objavljena v Uradnem listu Evropske unije [2].
As no statement of objection under Article 7 of Regulation (EC) No 510/2006 has been received by the Commission, that name should therefore be entered in the register,
Ker Komisija ni prejela nobenega ugovora v skladu s členom 7 Uredbe (ES) št. 510/2006, je treba navedeno ime registrirati –
OJ C 49, 28.2.2009, p. 9.
UL C 49, 28.2.2009, str. 9.
Traditional Grimsby Smoked Fish (PGI)
Traditional Grimsby Smoked Fish (ZGO)
Regulation (EC) No 987/2009 of the European Parliament and of the Council
Uredba (ES) št. 987/2009 Evropskega parlamenta in Sveta
laying down the procedure for implementing Regulation (EC) No 883/2004 on the coordination of social security systems
o določitvi podrobnih pravil za izvajanje Uredbe (ES) št. 883/2004 o koordinaciji sistemov socialne varnosti
Having regard to the Treaty establishing the European Community, and in particular Articles 42 and 308 thereof,
ob upoštevanju Pogodbe o ustanovitvi Evropske skupnosti ter zlasti členov 42 in 308 Pogodbe,
Having regard to Regulation (EC) No 883/2004 of the European Parliament and of the Council of 29 April 2004 on the coordination of social security systems [1], and in particular Article 89 thereof,
ob upoštevanju Uredbe (ES) št. 883/2004 Evropskega parlamenta in Sveta z dne 29. aprila 2004 o koordinaciji sistemov socialne varnosti [1] in zlasti člena 89 Uredbe,
Regulation (EC) No 883/2004 modernises the rules on the coordination of Member States’ social security systems, specifying the measures and procedures for implementing them and simplifying them for all the players involved.
Uredba (ES) št. 883/2004 posodablja pravila za koordinacijo sistemov socialne varnosti držav članic z določitvijo ukrepov in postopkov za njihovo izvajanje ter njihovo poenostavitvijo v korist vseh zadevnih akterjev.
Implementing rules should be laid down.
Treba bi bilo določiti podrobna pravila za njeno izvajanje.